Pharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitis

Clinical Pharmacokinetics
Federico PeaMario Furlanut

Abstract

To assess the pharmacokinetic and pharmacodynamic behaviour of moxifloxacin in 15 consecutive elderly patients with acute exacerbation of chronic bronchitis (AECB) treated with the fixed oral moxifloxacin 400 mg/day regimen with the intent of verifying which degree of exposure may be ensured by this standard regimen against AECB pathogens. This was an open-label, observational, pharmacokinetic-pharmacodynamic study. Blood samples were collected at steady state at appropriate intervals. Moxifloxacin plasma concentrations were analysed by means of high-performance liquid chromatography. Standard pharmacokinetic parameters and pharmacodynamic determinants (peak concentration [C(max)]/minimum inhibitory concentration [MIC], area under the plasma concentration-time curve during the 24-hour observational period [AUC(24)]/MIC, pharmacodynamic breakpoints [PDBPs]) were assessed. The mean estimated pharmacokinetic parameters (C(max) 4.40 mg/L at 1.4 hours, AUC(24) 42.67 mg . h/L, elimination half-life 12.55 hours, total body clearance 0.16 L/h/kg) were generally similar to those observed in both young and elderly historic controls (except for higher-dose normalised C(max) and lower volume of distribution of the central compartment). Med...Continue Reading

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Mar 22, 1995·JAMA : the Journal of the American Medical Association·S SaintD Grady
May 1, 1993·Antimicrobial Agents and Chemotherapy·A ForrestJ J Schentag
Mar 1, 1997·Journal of Pharmaceutical and Biomedical Analysis·F A WongS C Flor
Oct 29, 1997·Clinical Pharmacokinetics·M T Kinirons, P Crome
Jan 24, 1998·JAMA : the Journal of the American Medical Association·S L PrestonM Corrado
Jun 25, 1999·The Journal of Antimicrobial Chemotherapy·P D Lister, C C Sanders
Oct 29, 2000·Seminars in Respiratory Infections·S G Adams, A Anzueto
Mar 16, 2001·Current Opinion in Investigational Drugs·J F Barrett
Mar 17, 2001·The Journal of Antimicrobial Chemotherapy·F BarchiesiM A Viviani
Apr 3, 2001·Annals of Internal Medicine·V SnowUNKNOWN Joint Expert Panel on Chronic Obstructive Pulmonary Disease of the American College of Chest Physicians and the American Col
May 1, 2001·Clinical Pharmacokinetics·A AminimanizaniR Jelliffe
Jun 5, 2001·The Journal of Antimicrobial Chemotherapy·P D Lister, C C Sanders
Feb 7, 2002·The European Respiratory Journal·R Pauwels
Jun 27, 2002·Expert Opinion on Investigational Drugs·Lisa L DeverW G Johanson
Jan 15, 2003·Current Infectious Disease Reports·Sanjay Sethi
Feb 14, 2003·Journal of Chemotherapy·C GrassiUNKNOWN SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica
Aug 14, 2003·Experimental Gerontology·Klaus Turnheim
Sep 25, 2003·Antimicrobial Agents and Chemotherapy·Federico PeaMario Furlanut
Oct 10, 2003·Clinical Pharmacology and Therapeutics·Nicolas SimonBernard Bruguerolle
Oct 25, 2003·Metabolism: Clinical and Experimental·Rudolf E Noble
Feb 26, 2004·Drugs & Aging·Anna Maria Ferrara, Anna Maria Fietta
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael S Niederman
Dec 14, 2004·Clinical Pharmacology and Therapeutics·Zourab BebiaRobert A Branch

❮ Previous
Next ❯

Citations

Jul 9, 2013·International Journal of Antimicrobial Agents·Paschalina KontouIoannis Kioumis
Mar 25, 2008·Therapeutics and Clinical Risk Management·David Rp Guay
Nov 10, 2007·Journal of Veterinary Pharmacology and Therapeutics·A M Abd El-AtyJ-H Shim
Sep 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Federico Pea
May 19, 2010·Expert Review of Respiratory Medicine·Timothy E Albertson, Andrew L Chan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.